Embark Clinical Trial: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer: https://www.nejm.org/doi/full/10.1056...

Donate to PCRI: https://pcri.org/donate/'>https://pcri.org/donate/
For more information, visit https://pcri.org

1:02 What was the outcome of the recent EMBARK trial?
5:27 What side effects are typically related to Lupron?
6:08 Is combination therapy going to become increasingly prescribed?
7:15 Is combination therapy advisable for high Gleason scores?
8:54 Can you use any second generation hormone therapy for combination therapy?
9:58 Alex's conclusions
11:49 If you need help


Don't know your stage? Take the quiz: visit http://www.prostatecancerstaging.org

To learn more about prostate cancer, visit http://www.pcri.org

Sign up for our newsletter here to receive the latest updates on prostate cancer and the PCRI: https://pcri.org/join

Who we are:

The Prostate Cancer Research Institute (PCRI) is a 501(c)(3) notforprofit organization that is dedicated to helping you research your treatment options. We understand that you have many questions, and we can help you find the answers that are specific to your case. All of our resources are designed by a multidisciplinary team of advocates and expert physicians for patients. We believe that by educating yourself about the disease, you will have more productive interactions with your medical professionals and receive betterindividualized care. Feel free to explore our website at pcri.org or contact our free helpline with any questions that you have at pcri.org/helpline. Our Federal Tax ID # is 954617875 and qualifies for maximum charitable gift deductions by individual donors.